Tom Price Appointment Bodes Well For Biotech In 2017

Tom Price Appointment Bodes Well For Biotech In 2017


Biotechnology stocks, particularly pharmaceutical stocks, are likely to do well in 2017 for several reasons. The likely appointment of Dr. Tom Price to serve in Donald Trump's cabinet as Secretary of Health and Human Services will be a major plus for 2017.



from Biotech News